Applied Filters
Genentech refused appeal in Herceptin case
Justice Colin Birss has refused Roche’s biotechnology subsidiary Genentech the permission to appeal against an English High Court decision in which two patents covering its blockbuster breast cancer drug, Herceptin (trastuzumab), were revoked.
Mylan quashes morning-after pill dosage patent
Generics (UK) Limited, the UK arm of Mylan, has succeeded in invalidating a patent held by Hungarian pharmaceutical company Richter Gedeon at the English High Court.
Lilly’s Alimta dosage patent invalidated at English High Court
The English High Court has ruled that a patent covering vitamin dosage regimens for Eli Lilly’s lung cancer drug Alimta (pemetrexed disodium) would not be infringed by generic competitors.
Bayer buys Merck’s consumer care arm for $14.2bn
Bayer AG has agreed to buy New Jersey-based Merck’s consumer care business for $14.2 billion, the companies announced today (May 6).
HGF promotes Nelson to partner
HGF has promoted Mike Nelson to partner. He joined the firm last year to work with the pharmaceutical and chemistry teams after arriving from AstraZeneca.
AstraZeneca ‘has value’ says former Pfizer lawyer
AstraZeneca’s portfolio does not appear to offer a long pipeline of marketed products with long periods of exclusivity, says Jason Rutt, head of the patents group at Rouse in London and former head of Pfizer’s UK patent department.
Novartis and GSK team in $14.5b IP exchange
Novartis and GSK have agreed to create a consumer healthcare business in a joint venture that involves the exchange of assets worth billions of dollars.
UK High Court strikes down Herceptin patents
The UK High Court has invalidated two patents covering Roche’s breast cancer drug Herceptin (trastuzumab) after a challenge by generic drug maker Hospira.
Mallinckrodt picks up Acthar in Questcor merger
Dublin-based Mallinckrodt Pharmaceuticals has announced it will buy US biopharmaceutical company Questcor Pharmaceuticals for $5.6 billion.
EPO staff set to strike for seven days
Staff at the European Patent Office will hold seven days of strike action starting this week, it has been confirmed.
